Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies
Open accessThe DOI matches its Crossref record; 238 of the 239 references it cites were found in a registry or an index.
Abstract
Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the Aβ peptide in Alzheimer’s disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye. The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years. AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E ɛ4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral Aβ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“has been shown in a wide range of studies to contribute significantly to the pathogenesis and progression of AD2,8–19.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“leading to dysfunction and loss of synapses and eventual neuronal death1,2.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD pathology occurs well before (up to two decades) the onset of clinical symptoms2–4.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by an accumulation of senile plaques (SP) [composed mostly of fibrillary amyloid beta-peptide (Aβ) and dystrophic neurites] and neurofibrillary tangles (NFT) [composed of hyperphosphorylated tau protein] in the brain”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Research from our laboratories11,12,34 and many others2,4,8,10 has shown that inefficient glucose utilization (and thus impaired ATP production) and oxidative damage are intimately related.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationThe precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · cited 1×
“A peptides are hydrophobic 39–43 amino acid long products generated by the sequential proteolytic processing of the amyloid- protein precursor (A PP) [5, 6].”
BackgroundSelf-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 1×
“A peptides are hydrophobic 39–43 amino acid long products generated by the sequential proteolytic processing of the amyloid- protein precursor (A PP) [5, 6].”
BackgroundSelf-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Self-citationTalbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 1×
“The brains of patients with MCI and AD are functionally insulin resistant [27], and amyloid clearance rate, neuroinflammation, and synaptic dysfunction, which have all been linked to APOE 4 alleles, are also influenced by increased brain insulin levels [28].”
BackgroundCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“In AD subjects, the CSF concentration of A 42 decreases over time, while 181-phospho-tau and total tau concentrations increase, when compared to healthy controls (including patients with psychiatric disorders such as depression) [110].”
BackgroundMicrotubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,778
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 22×
“Collaborating with these CSIRO researchers, we then found abnormal numbers of chromosome 17 and 21 (aneuploidy) in AD compared to age-matched control buccal cell samples, significantly greater amounts of DNA/cell and greater numbers of abnormal nuclear shapes were found in both MCI and AD compared to controls [157], y…”
BackgroundInfluentialNorthey, J. M., Cherbuin, N., Pumpa, K. L., Smee, D. J., & Rattray, B. (2018) · British Journal of Sports Medicine · doi:10.1136/bjsports-2016-096587 · Cited by 1,380
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348 · cited 1×
“Therefore, a method has recently been developed to produce a single common quantitative output value, called the Centiloid, for A imaging across tracers and imaging analysis approaches, to improve clinical and research use of these A tracers [103].”
MethodSelf-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 1×
“In 2007, Ray and collaborators devised a plasma biomarker panel of 18 proteins that was able to predict the conversion to AD 2–6 years later [116].”
BackgroundMasters, C. L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R. N., & Beyreuther, K. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb04000.x · Cited by 1,042
Self-citationSleep disturbances increase the risk of dementia: a systematic review and meta-analysis
Shi, L., Chen, S.-J., Ma, M.-Y., Bao, Y.-P., Han, Y., Wang, Y.-M., Shi, J., Vitiello, M. V., & Lu, L. (2018) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2017.06.010 · Cited by 1,009
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · cited 15×
“For AIBL, the MRI parameters of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were adopted, and the PiB-PET acquisition and neuropsychological tests were designed to permit comparison and pooling with ADNI data.”
BackgroundInfluentialSelf-citationEllis, K. A., Bush, A. I., Darby, D., De Fazio, D., Foster, J., Hudson, P., Lautenschlager, N. T., Lenzo, N., Martins, R. N., Maruff, P., et al. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209009405 · Cited by 968
Self-citationOxidative stress in Alzheimer’s disease
Smith, M. A., Rottkamp, C. A., Nunomura, A., Raina, A. K., & Perry, G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00040-5 · Cited by 895
O’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Self-citationHerrero-Mendez, A., Almeida, A., Fernández, E., Maestre, C., Moncada, S., & Bolaños, J. P. (2009) · Nature Cell Biology · doi:10.1038/ncb1881 · Cited by 844
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833
Self-citationApolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases
Huang, Y., & Mahley, R. W. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.025 · Cited by 829 · cited 1×
“These include apoE effects on vascular function, neuroinflammation, metabolism, synaptic plasticity, and transcriptional regulation [72, 73].”
BackgroundPatton, N., Aslam, T., MacGillivray, T., Pattie, A., Deary, I. J., & Dhillon, B. (2005) · Journal of Anatomy · doi:10.1111/j.1469-7580.2005.00395.x · Cited by 807 · cited 1×
“The diagnostic potential of the eye has been investigated widely, as it shares many neural and vascular similarities to the brain and potentially reflects the brain pathology [139, 140].”
BackgroundapoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 1×
“barrier [48], and lower cellular uptake and lysosomal”
BackgroundDiabetes mellitus and risk of dementia: A meta‐analysis of prospective observational studies
Gudala, K., Bansal, D., Schifano, F., & Bhansali, A. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12087 · Cited by 727
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701 · cited 1×
“A imaging with PET is therefore contributing to the development of more effective therapies by allowing better selection of patients for anti-A therapy trials and providing a means to measure their effectiveness in removing A from the brain [101, 102].”
MethodAssociation of diabetes mellitus and dementia, the Rotterdam study
Ott, A., Stolk, R. P., Hofman, A., van Harskamp, F., Grobbee, D. E., & Breteler, M. M. B. (1996) · Diabetologia · doi:10.1007/s001250050588 · Cited by 677
Koronyo-Hamaoui, M., Koronyo, Y., Ljubimov, A. V., Miller, C. A., Ko, M. K., Black, K. L., Schwartz, M., & Farkas, D. L. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.06.020 · Cited by 672 · cited 1×
“The eye itself has been shown to produce A PP and accumulate A , and novel A -binding agents such as curcumin are showing promise as detection agents [140, 141, 153].”
BackgroundThree dimensions of the amyloid hypothesis: time, space and 'wingmen'
Musiek, E. S., & Holtzman, D. M. (2015) · Nature Neuroscience · doi:10.1038/nn.4018 · Cited by 662
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602 · cited 1×
“The implementation of the new biomarker criteria for the AD spectrum found that about 70% of healthy elderly controls did not fit the three categories [95], where 43% had no positive marker of amyloidosis or neurodegeneration, and 23% were classified with neurodegeneration without evidence”
MethodOvod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.06.2266 · Cited by 585 · cited 20×
“Imaging techniques using PiBPET that show gradual A accumulation in the brain, as well as the measurement of CSF levels of A 42, and phosphorylated tau are proving to be relatively reliable indicators of imminent AD [76]; however these are relatively expensive and invasive diagnostic techniques that, while serving as…”
BackgroundInfluentialEvaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573 · cited 1×
“Other studies have suggested an assay using A 42 and T-tau levels can accurately discriminate AD from controls by means of a discrimination line, which has been validated in clinical practice [113] and in autopsy-confirmed patients, with sensitivity levels of 100% and specificity of 91% [114].”
ResultTesting the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550 · cited 1×
“The detection of A pathology at the presymptomatic stages is of crucial importance because it is precisely the group that may benefit the most from therapies aimed at reducing or eliminating A from the brain before irreversible neuronal or synaptic loss occurs [100].”
BackgroundAmyloid‐β Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress
Smith, M. A., Hirai, K., Hsiao, K., Pappolla, M. A., Harris, P. L. R., Siedlak, S. L., Tabaton, M., & Perry, G. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70052212.x · Cited by 547 · cited 1×
“Many studies have since shown that levels of reduced glutathione (as well as the ratio of reduced:oxidized glutathione and levels of the enzyme glutathione-S-transferase) are lower in AD as well as in MCI [34–36], and in fact a plethora of pathological changes have been linked to oxidative damage, from the earliest st…”
BackgroundLee, S., Viqar, F., Zimmerman, M. E., Narkhede, A., Tosto, G., Benzinger, T. L. S., Marcus, D. S., Fagan, A. M., Goate, A., Fox, N. C., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24647 · Cited by 542
Self-citationEvidence for brain glucose dysregulation in Alzheimer's disease
An, Y., Varma, V. R., Varma, S., Casanova, R., Dammer, E., Pletnikova, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.011 · Cited by 507 · cited 1×
“Many studies having been carried out since then; it is now clear that abnormalities in glucose metabolism, and changes linked to insulin resistance and T2D, may be some of the earliest pathogenic changes in AD [167, 168].”
BackgroundVerdile, G., Keane, K. N., Cruzat, V. F., Medic, S., Sabale, M., Rowles, J., Wijesekara, N., Martins, R. N., Fraser, P. E., & Newsholme, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/105828 · Cited by 495 · cited 5×
“In contrast, adherence to a traditional Mediterranean diet (MeDi) [8] is known to be associated with longevity and good health [192]; similarly, the traditional Okinawa diet, along with an active and social lifestyle, is also associated with longevity and good health [193].”
BackgroundInfluentialSelf-citationReiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061509598 · Cited by 467
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434
Self-citationMechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431 · cited 1×
“A imaging with PET is therefore contributing to the development of more effective therapies by allowing better selection of patients for anti-A therapy trials and providing a means to measure their effectiveness in removing A from the brain [101, 102].”
MethodDaulatzai, M. A. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23777 · Cited by 429
Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease
Doecke, J. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1282 · Cited by 421
Self-citationRole of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus
Akash, M. S. H., Rehman, K., & Chen, S. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24402 · Cited by 407 · cited 2×
“Oxidative stress and inflammation are common to both conditions, and signs of these include higher levels of reactive oxygen species [170], an increase in advanced glycation end products [170], detrimental actions of the receptor for advanced glycation end products [171], increases in inflammatory cytokines TNF- , IL-…”
BackgroundSex and the development of Alzheimer's disease
Pike, C. J. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23827 · Cited by 402
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500579102 · Cited by 401
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
Benzinger, T. L. S., Blazey, T., Jack, C. R., Koeppe, R. A., Su, Y., Xiong, C., Raichle, M. E., Snyder, A. Z., Ances, B. M., Bateman, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317918110 · Cited by 391
Self-citationButterfield, D. A., Poon, H. F., St. Clair, D., Keller, J. N., Pierce, W. M., Klein, J. B., & Markesbery, W. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.11.002 · Cited by 377
Relationship between atrophy and β‐amyloid deposition in Alzheimer disease
Chételat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D., Ellis, K. A., Szoeke, C., Martins, R. N., O'Keefe, G. J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21955 · Cited by 373
Self-citationDavies, L., Wolska, B., Hilbich, C., Multhaup, G., Martins, R., Simms, G., Beyreuther, K., & Masters, C. L. (1988) · Neurology · doi:10.1212/wnl.38.11.1688 · Cited by 369
Self-citationGoldstein, L. E., Muffat, J. A., Cherny, R. A., Moir, R. D., Ericsson, M. H., Huang, X., Mavros, C., Coccia, J. A., Faget, K. Y., Fitch, K. A., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12981-9 · Cited by 363
Self-citationExercise Plays a Preventive Role Against Alzheimer's Disease
Radak, Z., Hart, N., Sarga, L., Koltai, E., Atalay, M., Ohno, H., & Boldogh, I. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091531 · Cited by 316 · cited 1×
“Numerous studies have reported positive impacts of physical activity on cognitive function [204, 205].”
BackgroundSuspected non-Alzheimer disease pathophysiology — concept and controversy
Jack, C. R., Knopman, D. S., Chételat, G., Dickson, D., Fagan, A. M., Frisoni, G. B., Jagust, W., Mormino, E. C., Petersen, R. C., Sperling, R. A., et al. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.251 · Cited by 306
Self-citationGlutathione peroxidase activity in Parkinson's disease brain
Kish, S. J., Morito, C., & Hornykiewicz, O. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90078-3 · Cited by 299
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Initiative, T. A. D. N., Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Figurski, M., Coart, E., Blennow, K., Soares, H., Simon, A. J., Lewczuk, P., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0808-0 · Cited by 298 · cited 1×
“Imaging techniques using PiBPET that show gradual A accumulation in the brain, as well as the measurement of CSF levels of A 42, and phosphorylated tau are proving to be relatively reliable indicators of imminent AD [76]; however these are relatively expensive and invasive diagnostic techniques that, while serving as…”
MethodRetinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease
Frost, S., Kanagasingam, Y., Sohrabi, H., Vignarajan, J., Bourgeat, P., Salvado, O., Villemagne, V, Rowe, C. C., Lance Macaulay, S., Szoeke, C., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.150 · Cited by 297
Self-citationAlzheimer's β-Amyloid Peptides Compete for Insulin Binding to the Insulin Receptor
Xie, L., Helmerhorst, E., Taddei, K., Plewright, B., van Bronswijk, W., & Martins, R. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-10-j0001.2002 · Cited by 291 · cited 1×
“We found reduced insulin binding and receptor autophosphorylation, with the reduction in binding caused by a decrease in the affinity of insulin binding to the insulin receptor [178], suggesting that A could compete directly with insulin binding.”
BackgroundSelf-citationPolarization sensitive optical coherence tomography in the human eye
Pircher, M., Hitzenberger, C. K., & Schmidt-Erfurth, U. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.06.003 · Cited by 288 · cited 1×
“Polarization-sensitive optical coherence tomography, which has been shown to detect ADassociated birefringence due to microtubule damage, is a sensitive new technique [146].”
MethodMediterranean diet and longevity
Trichopoulou, A., & Vasilopoulou, E. (2000) · British Journal Of Nutrition · doi:10.1079/096582197388554 · Cited by 284
Rabinovici, G. D., Furst, A. J., Alkalay, A., Racine, C. A., O’Neil, J. P., Janabi, M., Baker, S. L., Agarwal, N., Bonasera, S. J., Mormino, E. C., et al. (2010) · Brain · doi:10.1093/brain/awp326 · Cited by 280 · cited 1×
“The lack of a strong association between A deposition and measures of cognition, synaptic activity, and neurodegeneration in AD, in addition to the evidence of A deposition in a high percentage of MCI and asymptomatic healthy controls, suggests that A deposition is an early and necessary, though not sufficient, cause…”
ResultHealthy aging diets other than the Mediterranean: A focus on the Okinawan diet
Willcox, D. C., Scapagnini, G., & Willcox, B. J. (2014) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2014.01.002 · Cited by 273 · cited 1×
“In contrast, adherence to a traditional Mediterranean diet (MeDi) [8] is known to be associated with longevity and good health [192]; similarly, the traditional Okinawa diet, along with an active and social lifestyle, is also associated with longevity and good health [193].”
BackgroundThe role of type 2 diabetes in neurodegeneration
Verdile, G., Fuller, S. J., & Martins, R. N. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.008 · Cited by 272 · cited 3×
“High carbohydrate diets are thought to contribute to insulin resistance, which is associated with a host of peripheral changes that can all impact on AD pathogenesis, including hyperglycemia, hyperinsulinemia, dyslipidemia, and inflammation [168].”
BackgroundSelf-citationCheung, C. Y.-L., Ong, Y. T., Hilal, S., Ikram, M. K., Low, S., Ong, Y. L., Venketasubramanian, N., Yap, P., Seow, D., Chen, C. L. H., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141659 · Cited by 270 · cited 1×
“However, the specificity of the RNFL thickness and other eye biomarkers is low due to confounding factors such as age and comorbid eye disorders including glaucoma [142, 145].”
BackgroundSleep Quality and 1-Year Incident Cognitive Impairment in Community-Dwelling Older Adults
Potvin, O., Lorrain, D., Forget, H., Dubé, M., Grenier, S., Préville, M., & Hudon, C. (2012) · Sleep · doi:10.5665/sleep.1732 · Cited by 267
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia
Engelborghs, S., De Vreese, K., Van de Casteele, T., Vanderstichele, H., Van Everbroeck, B., Cras, P., Martin, J.-J., Vanmechelen, E., & De Deyn, P. P. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.016 · Cited by 257 · cited 1×
“Other studies have suggested an assay using A 42 and T-tau levels can accurately discriminate AD from controls by means of a discrimination line, which has been validated in clinical practice [113] and in autopsy-confirmed patients, with sensitivity levels of 100% and specificity of 91% [114].”
ResultVillain, N., Chételat, G., Grassiot, B., Bourgeat, P., Jones, G., Ellis, K. A., Ames, D., Martins, R. N., Eustache, F., Salvado, O., et al. (2012) · Brain · doi:10.1093/brain/aws125 · Cited by 255
Self-citationGoozee, K. G., Shah, T. M., Sohrabi, H. R., Rainey-Smith, S. R., Brown, B., Verdile, G., & Martins, R. N. (2016) · British Journal of Nutrition · doi:10.1017/s0007114515004687 · Cited by 244 · cited 1×
“Nevertheless, as described in our review [201], in vitro studies have indicated that A metabolism is altered by curcumin, and animal studies report that curcumin may influence brain function and dementia development, most likely due to antioxidant and anti-inflammatory properties.”
BackgroundSelf-citationPlasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
Hu, W. T., Holtzman, D. M., Fagan, A. M., Shaw, L. M., Perrin, R., Arnold, S. E., Grossman, M., Xiong, C., Craig-Schapiro, R., Clark, C. M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318266fa70 · Cited by 241
Kalmijn, S., Launer, L. J., Lindemans, J., Bots, M. L., Hofman, A., & Breteler, M. M. B. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010000 · Cited by 237 · cited 1×
“A relationship between plasma homocysteine levels, cognitive performance, and the risk of AD has previously been reported, particularly in longitudinal studies with 5–9 year follow-up, showing increases in homocysteine correlating with cognitive decline [135], though some studies have not found this correlation [136],…”
ResultGlutathione redox imbalance in brain disorders
Gu, F., Chauhan, V., & Chauhan, A. (2015) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0000000000000134 · Cited by 236
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes
Miklossy, J., Qing, H., Radenovic, A., Kis, A., Vileno, B., Làszló, F., Miller, L., Martins, R. N., Waeber, G., Mooser, V., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.019 · Cited by 235 · cited 11×
“We have also shown that plasma A 40 and A 42 were lower in individuals with T2D compared to others from the same community-based cohort without diabetes [183].”
BackgroundInfluentialSelf-citationMartins, R. N., Harper, C. G., Stokes, G. B., & Masters, C. L. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb00615.x · Cited by 234 · cited 1×
“We found that, compared to controls, levels of the enzymes glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase were both nearly doubled in the AD brains [33].”
BackgroundSelf-citationVandal, M., White, P. J., Tremblay, C., St-Amour, I., Chevrier, G., Emond, V., Lefrançois, D., Virgili, J., Planel, E., Giguere, Y., et al. (2014) · Diabetes · doi:10.2337/db14-0375 · Cited by 233 · cited 1×
“AD [189], and in a novel mouse model with overlap-”
BackgroundBrown, B. M., Peiffer, J. J., & Martins, R. N. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.162 · Cited by 228 · cited 1×
“Numerous studies have reported positive impacts of physical activity on cognitive function [204, 205].”
BackgroundSelf-citationSchuch, F. B., Vancampfort, D., Rosenbaum, S., Richards, J., Ward, P. B., Veronese, N., Solmi, M., Cadore, E. L., & Stubbs, B. (2016) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2016-1915 · Cited by 226
Rainey-Smith, S. R., Brown, B. M., Sohrabi, H. R., Shah, T., Goozee, K. G., Gupta, V. B., & Martins, R. N. (2016) · British Journal of Nutrition · doi:10.1017/s0007114516001203 · Cited by 224 · cited 1×
“Further longitudinal assessment is required to investigate changes in cognitive outcome [200].”
BackgroundSelf-citationRowe, C. C., Bourgeat, P., Ellis, K. A., Brown, B., Lim, Y. Y., Mulligan, R., Jones, G., Maruff, P., Woodward, M., Price, R., et al. (2013) · Annals of Neurology · doi:10.1002/ana.24040 · Cited by 222 · cited 22×
“Collaborating with these CSIRO researchers, we then found abnormal numbers of chromosome 17 and 21 (aneuploidy) in AD compared to age-matched control buccal cell samples, significantly greater amounts of DNA/cell and greater numbers of abnormal nuclear shapes were found in both MCI and AD compared to controls [157], y…”
MethodInfluentialSelf-citationApolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease
Liao, F., Yoon, H., & Kim, J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000383 · Cited by 221 · cited 1×
“These include apoE effects on vascular function, neuroinflammation, metabolism, synaptic plasticity, and transcriptional regulation [72, 73].”
BackgroundPlasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease
Soares, H. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1070 · Cited by 218
The Eye As a Biomarker for Alzheimer's Disease
Lim, J. K. H., Li, Q.-X., He, Z., Vingrys, A. J., Wong, V. H. Y., Currier, N., Mullen, J., Bui, B. V., & Nguyen, C. T. O. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00536 · Cited by 209
Homocysteine and Cognitive Decline in Healthy Elderly
McCaddon, A., Hudson, P., Davies, G., Hughes, A., Williams, J. H. H., & Wilkinson, C. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051275 · Cited by 207 · cited 1×
“A relationship between plasma homocysteine levels, cognitive performance, and the risk of AD has previously been reported, particularly in longitudinal studies with 5–9 year follow-up, showing increases in homocysteine correlating with cognitive decline [135], though some studies have not found this correlation [136],…”
ResultBharadwaj, P., Wijesekara, N., Liyanapathirana, M., Newsholme, P., Ittner, L., Fraser, P., & Verdile, G. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161192 · Cited by 202
Self-citationMolecular links between Alzheimer’s disease and diabetes mellitus
Yang, Y., & Song, W. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.07.009 · Cited by 201 · cited 1×
“Oxidative stress and inflammation are common to both conditions, and signs of these include higher levels of reactive oxygen species [170], an increase in advanced glycation end products [170], detrimental actions of the receptor for advanced glycation end products [171], increases in inflammatory cytokines TNF- , IL-…”
BackgroundMandal, P. K., Tripathi, M., & Sugunan, S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.047 · Cited by 200
Positron Emission Tomography in the Study of Aging and Senile Dementia
Ferris, S. H., de Leon, M. J., Wolf, A. P., Farkas, T., Christman, D. R., Reisberg, B., Fowler, J. S., MacGregor, R., Goldman, A., George, A. E., et al. (1980) · Neurobiology of Aging · doi:10.1016/0197-4580(80)90005-6 · Cited by 198 · cited 1×
“Changes in glucose use in AD brains compared to elderly controls had been detected as far back as 1980 [165].”
BackgroundFernando, W. M. A. D. B., Martins, I. J., Goozee, K. G., Brennan, C. S., Jayasena, V., & Martins, R. N. (2015) · British Journal of Nutrition · doi:10.1017/s0007114515001452 · Cited by 198 · cited 1×
“There is already mounting evidence that coconut oil may be beneficial in the treatment of obesity, dyslipidemia, elevated LDL, insulin resistance, and hypertension (all risk factors for AD), and certain phenolic compounds and hormones (cytokinins) found in coconut may help prevent the aggregation of A [203].”
BackgroundSelf-citationExercise prescription to reverse frailty
Bray, N. W., Smart, R. R., Jakobi, J. M., & Jones, G. R. (2016) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2016-0226 · Cited by 195
Sleep Disturbance is Associated with Incident Dementia and Mortality
Sterniczuk, R., Theou, O., Rusak, B., & Rockwood, K. (2013) · Current Alzheimer Research · doi:10.2174/15672050113109990134 · Cited by 185
Adherence to a Mediterranean diet and Alzheimer’s disease risk in an Australian population
Gardener, S., Gu, Y., Rainey-Smith, S. R., Keogh, J. B., Clifton, P. M., Mathieson, S. L., Taddei, K., Mondal, A., Ward, V. K., Scarmeas, N., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.91 · Cited by 185
Self-citationDoré, V., Villemagne, V. L., Bourgeat, P., Fripp, J., Acosta, O., Chetélat, G., Zhou, L., Martins, R., Ellis, K. A., Masters, C. L., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1062 · Cited by 183
Self-citationHenderson, V. W. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.05.010 · Cited by 181 · cited 1×
“age, or once AD symptoms have appeared have rarely been found to be beneficial; some have even been found to be detrimental [222].”
BackgroundCognitive Function and Decline in Obesity
Sellbom, K. S., & Gunstad, J. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-111073 · Cited by 178
18F-Florbetaben PET beta-amyloid binding expressed in Centiloids
Rowe, C. C., Doré, V., Jones, G., Baxendale, D., Mulligan, R. S., Bullich, S., Stephens, A. W., De Santi, S., Masters, C. L., Dinkelborg, L., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3749-6 · Cited by 178 · cited 1×
“Among them, 18F-NAV4694 and 18F-florbetaben have been the first two A tracers validated using the Centiloid approach [104, 105].”
MethodSelf-citationLi, J., Kanekiyo, T., Shinohara, M., Zhang, Y., LaDu, M. J., Xu, H., & Bu, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.420224 · Cited by 177 · cited 1×
“trafficking in brain cells [49], properties that would”
BackgroundHenke, H., & Lang, W. (1983) · Brain Research · doi:10.1016/0006-8993(83)90880-6 · Cited by 176 · cited 1×
“It had also been shown in 1976 that levels of choline acetyltransferase (necessary for the synthesis of the neurotransmitter acetylcholine) were lower in AD, particularly in regions most affected such as the cortex and hippocampus [31], thus it was logical to suggest perhaps the pathology in AD involved oxidative stre…”
BackgroundGharbiya, M., Trebbastoni, A., Parisi, F., Manganiello, S., Cruciani, F., D'Antonio, F., De Vico, U., Imbriano, L., Campanelli, A., & De Lena, C. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-132039 · Cited by 174 · cited 1×
“Various other eye abnormalities have been linked to AD, such as changes in choroidal thickness [147], though this could be present in other eye conditions.”
BackgroundAccelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition
Chételat, G., Villemagne, V. L., Villain, N., Jones, G., Ellis, K. A., Ames, D., Martins, R. N., Masters, C. L., & Rowe, C. C. (2012) · Neurology · doi:10.1212/wnl.0b013e318246d67a · Cited by 172
Self-citationPhysical Activity and Alzheimer Disease: A Protective Association
Santos-Lozano, A., Pareja-Galeano, H., Sanchis-Gomar, F., Quindós-Rubial, M., Fiuza-Luces, C., Cristi-Montero, C., Emanuele, E., Garatachea, N., & Lucia, A. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.024 · Cited by 164
Dietary patterns and cognitive decline in an Australian study of ageing
Gardener, S. L., Rainey‐Smith, S. R., Barnes, M. B., Sohrabi, H. R., Weinborn, M., Lim, Y. Y., Harrington, K., Taddei, K., Gu, Y., Rembach, A., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.79 · Cited by 159
Self-citationO'Bryant, S. E., Xiao, G., Barber, R., Huebinger, R., Wilhelmsen, K., Edwards, M., Graff-Radford, N., Doody, R., Diaz-Arrastia, R., for the Texas Alzheimer's Research & Care Consortium, et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028092 · Cited by 158
Self-citationThe Relationship between Sleep Quality and Brain Amyloid Burden
Brown, B. M., Rainey-Smith, S. R., Villemagne, V. L., Weinborn, M., Bucks, R. S., Sohrabi, H. R., Laws, S. M., Taddei, K., Macaulay, S. L., Ames, D., et al. (2016) · Sleep · doi:10.5665/sleep.5756 · Cited by 156 · cited 1×
“We found longer sleep latency to be associated with higher brain A burden, with a 30minute longer sleep latency potentially translating to an equivalent of 2 years of brain A accumulation [217].”
BackgroundSelf-citationTREM2 Function in Alzheimer’s Disease and Neurodegeneration
Ulrich, J. D., & Holtzman, D. M. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00313 · Cited by 154 · cited 1×
“Certain TREM2 mutations influence the risk of AD, and TREM2 is thought to be involved in A clearance; however, the exact relationship between these proteins is currently still being researched [74].”
BackgroundChételat, G., Villemagne, V. L., Pike, K. E., Ellis, K. A., Bourgeat, P., Jones, G., O’Keefe, G. J., Salvado, O., Szoeke, C., Martins, R. N., et al. (2011) · Brain · doi:10.1093/brain/awq383 · Cited by 153
Self-citationRetinal blood flow in mild cognitive impairment and Alzheimer's disease
Feke, G. T., Hyman, B. T., Stern, R. A., & Pasquale, L. R. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.01.004 · Cited by 151
Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging
Gupta, V. B., Laws, S. M., Villemagne, V. L., Ames, D., Bush, A. I., Ellis, K. A., Lui, J. K., Masters, C., Rowe, C. C., Szoeke, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318211c352 · Cited by 149
Self-citationLv, W., Du, N., Liu, Y., Fan, X., Wang, Y., Jia, X., Hou, X., & Wang, B. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9315-y · Cited by 147
Preclinical AD predicts decline in memory and executive functions in subjective complaints
van Harten, A. C., Smits, L. L., Teunissen, C. E., Visser, P. J., Koene, T., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a8418b · Cited by 143 · cited 1×
“from those elderly controls with no evidence of amyloidosis or neurodegeneration, suggesting a different, non-AD, underlying pathophysiological mechanism [97].”
BackgroundRoberts, B. R., Lind, M., Wagen, A. Z., Rembach, A., Frugier, T., Li, Q.-X., Ryan, T. M., McLean, C. A., Doecke, J. D., Rowe, C. C., et al. (2017) · Brain · doi:10.1093/brain/awx057 · Cited by 143 · cited 1×
“In AIBL studies, we have used A imaging as the gold standard for the validation of CSF assessments [89] and for the determination of the different biochemical pools of A in the brain [90].”
MethodSelf-citationMarksteiner, J., Kemmler, G., Weiss, E. M., Knaus, G., Ullrich, C., Mechtcheriakov, S., Oberbauer, H., Auffinger, S., Hinterhölzl, J., Hinterhuber, H., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.03.011 · Cited by 142 · cited 22×
“Collaborating with these CSIRO researchers, we then found abnormal numbers of chromosome 17 and 21 (aneuploidy) in AD compared to age-matched control buccal cell samples, significantly greater amounts of DNA/cell and greater numbers of abnormal nuclear shapes were found in both MCI and AD compared to controls [157], y…”
InfluentialStandardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale
Rowe, C. C., Jones, G., Doré, V., Pejoska, S., Margison, L., Mulligan, R. S., Chan, J. G., Young, K., & Villemagne, V. L. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171595 · Cited by 140 · cited 1×
“Among them, 18F-NAV4694 and 18F-florbetaben have been the first two A tracers validated using the Centiloid approach [104, 105].”
MethodSelf-citationIntense physical activity is associated with cognitive performance in the elderly
Brown, B. M., Peiffer, J. J., Sohrabi, H. R., Mondal, A., Gupta, V. B., Rainey-Smith, S. R., Taddei, K., Burnham, S., Ellis, K. A., Szoeke, C., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.118 · Cited by 136
Self-citationEvaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
Björkqvist, M., Ohlsson, M., Minthon, L., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029868 · Cited by 135 · cited 1×
“In 2008, one study suggested that a biomarker panel of only 5 proteins from the former 18-protein panel was sufficient to distinguish controls from AD with the same accuracy [117], yet in one study of the original 18-protein panel, only 3 proteins (epidermal growth factor (EGF), platelet-derived growth factor-homodime…”
Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging
Lui, J. K., for the AIBL Research Group, Laws, S. M., Li, Q.-X., Villemagne, V. L., Ames, D., Brown, B., Bush, A. I., De Ruyck, K., Dromey, J., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-090249 · Cited by 134
Self-citationChanges in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease
Rembach, A., Faux, N. G., Watt, A. D., Pertile, K. K., Rumble, R. L., Trounson, B. O., Fowler, C. J., Roberts, B. R., Perez, K. A., Li, Q., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.12.006 · Cited by 134
Self-citationAssociations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease
Verdile, G., Laws, S. M., Henley, D., Ames, D. J., Bush, A. I., Ellis, K. A., Faux, N. G., Gupta, V. B., Li, Q., Masters, C. L., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.147 · Cited by 133
Self-citationRosales-Corral, S., Tan, D.-X., Manchester, L., & Reiter, R. J. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/985845 · Cited by 128
Sultana, R., Piroddi, M., Galli, F., & Butterfield, D. A. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9593-0 · Cited by 126
Burnham, S. C., Faux, N. G., Wilson, W. J., Laws, S. M., Ames, D. J., Bedő, J., Bush, A. I., Doecke, J. D., Ellis, K. A., Head, R. J., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.40 · Cited by 125
Self-citationGolzan, S. M., Goozee, K., Georgevsky, D., Avolio, A., Chatterjee, P., Shen, K., Gupta, V., Chung, R., Savage, G., Orr, C. F., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0239-9 · Cited by 119 · cited 1×
“[150], adding evidence for the diagnostic potential of”
BackgroundSelf-citationWijesekara, N., Ahrens, R., Sabale, M., Wu, L., Ha, K., Verdile, G., & Fraser, P. E. (2017) · The FASEB Journal · doi:10.1096/fj.201700431r · Cited by 117
Self-citationIdentification of a 5-Protein Biomarker Molecular Signature for Predicting Alzheimer's Disease
Gómez Ravetti, M., & Moscato, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003111 · Cited by 116 · cited 1×
“In 2008, one study suggested that a biomarker panel of only 5 proteins from the former 18-protein panel was sufficient to distinguish controls from AD with the same accuracy [117], yet in one study of the original 18-protein panel, only 3 proteins (epidermal growth factor (EGF), platelet-derived growth factor-homodime…”
Buccal micronucleus cytome biomarkers may be associated with Alzheimer's disease
Thomas, P., Hecker, J. R., Faunt, J., & Fenech, M. F. (2007) · Mutagenesis · doi:10.1093/mutage/gem029 · Cited by 114
Di Domenico, F., Barone, E., Perluigi, M., & Butterfield, D. A. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6759 · Cited by 114
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
Niemantsverdriet, E., Valckx, S., Bjerke, M., & Engelborghs, S. (2017) · Acta Neurologica Belgica · doi:10.1007/s13760-017-0816-5 · Cited by 114 · cited 1×
“CSF studies have shown that the combined measurement of CSF A 42, total tau, and 181-phospho-tau levels can diagnose AD [111] with a sensitivity and specificity reaching 92 and 89%, respectively [112].”
BackgroundOcular Biomarkers for Early Detection of Alzheimer's Disease
Frost, S., Martins, R. N., & Kanagasingam, Y. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100819 · Cited by 106 · cited 2×
“The first studies to find changes in AD versus healthy controls discovered abnormal patterns in electroretinograms; later studies found enhanced pupil response to cholinergic drops, retinal nerve fiber layer (RNFL, ganglion cell axons) thinning as well as optic nerve degeneration [141, 142], which indicated widespread…”
BackgroundSelf-citationApoE genotypes in Australia: roles in early and late onset Alzheimerʼs disease and Downʼs syndrome
Martins, R. N., Clarnette, R., Fisher, C., Broe, G. A., Brooks, W. S., Montgomery, P., & Gandy, S. E. (1995) · NeuroReport · doi:10.1097/00001756-199507310-00012 · Cited by 105
Self-citationJohnson, L. A., Torres, E. R. S., Impey, S., Stevens, J. F., & Raber, J. (2017) · Scientific Reports · doi:10.1038/srep43701 · Cited by 103
Emoto, M., Langille, S. E., & Czech, M. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010785200 · Cited by 101 · cited 2×
“Tau has roles in insulin transport and secretion by the pancreatic -cells [184, 185], and can also mod- ulate insulin-dependent translocation of the glucose transporter, GLUT4 [186, 187], which is critical for glucose uptake by tissues.”
Moore, E. M., Ames, D. J., Mander, A. G., Carne, R. P., Brodaty, H., Woodward, M. C., Boundy, K. L., Ellis, K. A., Bush, A. I., Faux, N. G., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131265 · Cited by 98
Self-citationIncreased plasma apolipoprotein E (apoE) levels in Alzheimer's disease
Taddei, K., Clarnette, R., E. Gandy, S., & Martins, R. N. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13394-8 · Cited by 98 · cited 1×
“In later studies we investigated whether plasma apoE levels were altered in AD, and found significantly higher plasma apoE levels in both late-onset and early-onset AD patients who had not fasted [42].”
BackgroundSelf-citationSignal Transduction Cascades Associated with Oxidative Stress in Alzheimer's Disease
Petersen, R. B., Nunomura, A., Lee, H.-G., Casadesus, G., Perry, G., Smith, M. A., & Zhu, X. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11202 · Cited by 97 · cited 2×
“This build-up of A is thought to be initiated by various factors including oxidative stress and chronic inflammation [8, 9].”
BackgroundFaux, N. G., Ellis, K. A., Porter, L., Fowler, C. J., Laws, S. M., Martins, R. N., Pertile, K. K., Rembach, A., Rowe, C. C., Rumble, R. L., et al. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110752 · Cited by 95
Self-citationInvolvement of Aquaporin 4 in Astrocyte Function and Neuropsychiatric Disorders
Xiao, M., & Hu, G. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12267 · Cited by 95 · cited 1×
“, Translational Psychiatry, in press), an intriguing finding given that Aquaporin-4 is an astrocytic end-feet expressed water channel protein postulated to be involved in glymphatic system-mediated clearance of A from the brain [218].”
BackgroundOestrogen replacement therapy may improve memory functioning in the absence of APOE ε4
Burkhardt, M. S., Foster, J. K., Laws, S. M., Baker, L. D., Craft, S., Gandy, S. E., Stuckey, B. G. A., Clarnette, R., Nolan, D., Hewson-Bower, B., et al. (2004) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6302 · Cited by 94 · cited 1×
“In our own studies of healthy post-menopausal women given estrogen replacement therapy, we found some improvements in memory functioning and only in women who did not carry APOE 4 alleles [223], indicating yet another potential link between apoE and AD.”
Self-citationAPOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease
Lim, Y. Y., Villemagne, V. L., Pietrzak, R. H., Ames, D. J., Ellis, K. A., Harrington, K., Snyder, P. J., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.008 · Cited by 93
Self-citationEarly Detection of Amyloidopathy in Alzheimer's Mice by Hyperspectral Endoscopy
More, S. S., Beach, J. M., & Vince, R. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-17406 · Cited by 93 · cited 1×
“In a recent animal study, retinal A was identified using a novel hyperspectral imaging method in live mouse retina, without any extraneous agent [154].”
MethodAmyloid-β Induces Hepatic Insulin Resistance by Activating JAK2/STAT3/SOCS-1 Signaling Pathway
Zhang, Y., Zhou, B., Zhang, F., Wu, J., Hu, Y., Liu, Y., & Zhai, Q. (2012) · Diabetes · doi:10.2337/db11-0499 · Cited by 92
The Effects of Testosterone Supplementation on Cognitive Functioning in Older Men.
Wahjoepramono, E. J., Asih, P. R., Aniwiyanti, V., Taddei, K., Dhaliwal, S. S., Fuller, S. J., Foster, J. K., Carruthers, M. E., Verdile, G., Sohrabi, H. R., et al. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666151110125704 · Cited by 88 · cited 1×
“modest improvements on global cognition [230];”
Self-citationGenetics of Alzheimer's disease
Hutton, M., Pérez-Tur, J., & Hardy, J. (1998) · Essays in Biochemistry · doi:10.1042/bse0330117 · Cited by 88
Laws, S. M., Gaskin, S., Woodfield, A., Srikanth, V., Bruce, D., Fraser, P. E., Porter, T., Newsholme, P., Wijesekara, N., Burnham, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09577-4 · Cited by 85 · cited 1×
“Further, in AIBL, we have shown that increased insulin resistance in the cognitively normal older adults is associated with poorer performance across several cognitive domains, including episodic memory and executive function [169].”
MethodSelf-citationJohnstone, D., Milward, E. A., Berretta, R., Moscato, P., & Initiative, F. T. A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034341 · Cited by 82
Hall, E. D. (1989) · Critical Care Clinics · doi:10.1016/s0749-0704(18)30408-1 · Cited by 81 · cited 1×
“involved oxygen radical generation, lipid peroxidation, and cell death [30].”
BackgroundBiomarkers of Alzheimer's Disease Among Mexican Americans
O'Bryant, S. E., Xiao, G., Edwards, M., Devous, M., Gupta, V. B., Martins, R., Zhang, F., Barber, R., & for the Texas Alzheimer's Research and Care Consortium (TARCC) (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122074 · Cited by 80
Self-citationYang, D.-S., Small, D. H., Seydel, U., Smith, J. D., Hallmayer, J., Gandy, S. E., & Martins, R. N. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00561-2 · Cited by 76
Self-citationPlasma Aβ42 correlates positively with increased body fat in healthy individuals
Balakrishnan, K., Verdile, G., Mehta, P. D., Beilby, J., Nolan, D., Galvão, D. A., Newton, R., Gandy, S. E., & Martins, R. N. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-8305 · Cited by 75
Self-citationRasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.05.006 · Cited by 75
Petit, D., Montplaisir, J., Lorrain, D., & Gauthier, S. (1992) · Annals of Neurology · doi:10.1002/ana.410320208 · Cited by 74 · cited 2×
“Analysis of the spectra indicated that AD patients had much slower EEG readings during REM sleep when compared to being awake, and asymmetry on the awake EEG of AD patients was found to be even more prominent than on the REM sleep EEG [219].”
BackgroundLi, Q.-X., Villemagne, V. L., Doecke, J. D., Rembach, A., Sarros, S., Varghese, S., McGlade, A., Laughton, K. M., Pertile, K. K., Fowler, C. J., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150247 · Cited by 74
Self-citationReceptor for advanced glycation end-products in neurodegenerative diseases
Juranek, J., Ray, R., Banach, M., & Rai, V. (2015) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0003 · Cited by 73 · cited 1×
“Oxidative stress and inflammation are common to both conditions, and signs of these include higher levels of reactive oxygen species [170], an increase in advanced glycation end products [170], detrimental actions of the receptor for advanced glycation end products [171], increases in inflammatory cytokines TNF- , IL-…”
BackgroundAPOE-ε4 and APOE −491A polymorphisms in individuals with subjective memory loss
Laws, S. M., Clarnette, R., Taddei, K., Martins, G., Paton, A., Hallmayer, J. F., Almeida, O. P., Groth, D. M., Gandy, S., Förstl, H., et al. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001083 · Cited by 73
Self-citationShah, T. M., Gupta, S. M., Chatterjee, P., Campbell, M., & Martins, R. N. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.251 · Cited by 72 · cited 2×
“The diagnostic potential of the eye has been investigated widely, as it shares many neural and vascular similarities to the brain and potentially reflects the brain pathology [139, 140].”
BackgroundSelf-citationDiet and Inflammation in Alzheimer’s Disease and Related Chronic Diseases: A Review
Gardener, S. L., Rainey‐Smith, S. R., & Martins, R. N. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150765 · Cited by 70 · cited 1×
“Other antioxidant and anti-inflammatory food sources that have also been investigated by us and others include curcumin (a component of the spice turmeric), cinnamon, ginger, and the pepper family [25, 199].”
BackgroundSelf-citationApolipoprotein E influences amyloid-beta clearance from the murine periphery
Hone, E., Martins, I. J., Fonte, J., & Martins, R. N. (2003) · Journal of Alzheimer's Disease · doi:10.3233/jad-2003-5101 · Cited by 69
Self-citationEllis, K. A., Rowe, C. C., Villemagne, V. L., Martins, R. N., Masters, C. L., Salvado, O., Szoeke, C., Ames, D., & AIBL research group (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.009 · Cited by 68
Self-citationGoodwin, G. M. (1996) · PubMed · Cited by 68
Influence of BDNF Val66Met on the relationship between physical activity and brain volume
Brown, B. M., Bourgeat, P., Peiffer, J. J., Burnham, S., Laws, S. M., Rainey-Smith, S. R., Bartrés-Faz, D., Villemagne, V. L., Taddei, K., Rembach, A., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000867 · Cited by 66
Self-citationRapid Decline in Episodic Memory in Healthy Older Adults with High Amyloid-β
Lim, Y. Y., Pietrzak, R. H., Ellis, K. A., Jaeger, J., Harrington, K., Ashwood, T., Szoeke, C., Martins, R. N., Bush, A. I., Masters, C. L., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121516 · Cited by 65 · cited 1×
“Furthermore, while memory in the cognitively unimpaired adults with low A burden (A –) remained stable over 18-months, all aspects of episodic memory were observed to deteriorate substantially in A + non-demented participants [79, 80].”
ResultSelf-citationBrown, B. M., Sohrabi, H. R., Taddei, K., Gardener, S. L., Rainey‐Smith, S. R., Peiffer, J. J., Xiong, C., Fagan, A. M., Benzinger, T., Buckles, V., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.03.008 · Cited by 63 · cited 10×
“Whether higher levels of exercise are associated with protection against NAB accumulation, or whether decreases in exercise levels are a symptom of developing dementia, or a combination of the two, is yet to be determined.”
BackgroundInfluentialSelf-citationGonadotropins and Cognition in Older Women
Rodrigues, M. A., Verdile, G., Foster, J. K., Hogervorst, E., Joesbury, K., Dhaliwal, S., Corder, E. H., Laws, S. M., Hone, E., Prince, R., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13304 · Cited by 62 · cited 1×
“In some of our own studies we have shown that LH levels (and not testosterone) correlate with plasma A levels in elderly men [232], whereas in women, we have found high endogenous LH is associated with a lower cognitive score, particularly in women who are depressed [233].”
BackgroundSelf-citationAmyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor
Ling, X., Martins, R. N., Racchi, M., Craft, S., & Helmerhorst, E. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4504 · Cited by 61 · cited 1×
“Using an in vitro model, we showed that insulin could facilitate the release of A PP from cells transfected with insulin receptors, and that the addition of A could block this release [177].”
Self-citationDiabetes and Alzheimer’s Disease: Can Tea Phytochemicals Play a Role in Prevention?
Fernando, W. M. A. D. B., Somaratne, G., Goozee, K. G., Williams, S., Singh, H., & Martins, R. N. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161200 · Cited by 61 · cited 1×
“tochemicals) may inhibit A plaque formation, and enhance cognitive function [198].”
BackgroundSelf-citationAndrogens in the Etiology of Alzheimer's Disease in Aging Men and Possible Therapeutic Interventions
Fuller, S. J., Tan, R. S., & Martins, R. N. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-12202 · Cited by 60 · cited 1×
“However, there can be considerable variation, with some men experiencing much more severe declines in testosterone levels, and this age-related decline has also been linked to cognitive decline and AD risk [224].”
BackgroundSelf-citationAltered oxidation and signal transduction systems in fibroblasts from Alzheimer patients
Gibson, G., Martins, R., Blass, J., & Gandy, S. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00327-x · Cited by 60 · cited 1×
“oxidation and ion channel function [39].”
Self-citationSharman, M. J., Morici, M., Hone, E., Berger, T., Taddei, K., Martins, I. J., Lim, W. L. F., Singh, S., Wenk, M. R., Ghiso, J., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100141 · Cited by 54 · cited 1×
“When the APOE KO animals were treated with lipidated recombinant apoE 4, injected A 42 was retained in the plasma significantly longer, similar to the APOE 4 knock-in mice, when compared to the equivalent APOE 3 or 2 mice [21].”
MethodSelf-citationMaj, M., Gartner, W., Ilhan, A., Neziri, D., Attems, J., & Wagner, L. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0341 · Cited by 54 · cited 1×
“Tau has roles in insulin transport and secretion by the pancreatic -cells [184, 185], and can also mod-”
BackgroundSubjective Memory Complaints in APOE ɛ 4 Carriers are Associated with High Amyloid-β Burden
Zwan, M. D., Villemagne, V. L., Doré, V., Buckley, R., Bourgeat, P., Veljanoski, R., Salvado, O., Williams, R., Margison, L., Rembach, A., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150446 · Cited by 53
Self-citationBates, K. A., Sohrabi, H. R., Rainey-Smith, S. R., Weinborn, M., Bucks, R. S., Rodrigues, M., Beilby, J., Howard, M., Taddei, K., Martins, G., et al. (2017) · International Journal of Neuroscience · doi:10.1080/00207454.2016.1182527 · Cited by 53
Self-citationPlasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study
Chatterjee, P., Lim, W. L. F., Shui, G., Gupta, V. B., James, I., Fagan, A. M., Xiong, C., Sohrabi, H. R., Taddei, K., Brown, B. M., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150948 · Cited by 52 · cited 11×
“Whether higher levels of exercise are associated with protection against NAB accumulation, or whether decreases in exercise levels are a symptom of developing dementia, or a combination of the two, is yet to be determined.”
BackgroundInfluentialSelf-citationVerdile, G., Yeap, B. B., Clarnette, R. M., Dhaliwal, S., Burkhardt, M. S., Chubb, S. A. P., De Ruyck, K., Rodrigues, M., Mehta, P. D., Foster, J. K., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-14208 · Cited by 51 · cited 1×
“In some of our own studies we have shown that LH levels (and not testosterone) correlate with plasma A levels in elderly men [232], whereas in women, we have found high endogenous LH is associated with a lower cognitive score, particularly in women who are depressed [233].”
BackgroundSelf-citationDetrimental Effects of Apolipoprotein E4: Potential Therapeutic Targets in Alzheimers Disease
Mahley, R., Huang, Y., & Weisgraber, K. (2007) · Current Alzheimer Research · doi:10.2174/156720507783018334 · Cited by 51 · cited 1×
“The brains of patients with MCI and AD are functionally insulin resistant [27], and amyloid clearance rate, neuroinflammation, and synaptic dysfunction, which have all been linked to APOE 4 alleles, are also influenced by increased brain insulin levels [28].”
BackgroundLipidomic Profiles in Diabetes and Dementia
Huynh, K., Martins, R. N., & Meikle, P. J. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161215 · Cited by 51
Self-citationCognitive impairment among prostate cancer patients: An overview of reviews
Treanor, C. J., Li, J.-Y., & Donnelly, M. (2017) · European Journal of Cancer Care · doi:10.1111/ecc.12642 · Cited by 50 · cited 1×
“Observations of hypogonadal men and men on androgen deprivation therapy have shown that lower androgen levels can impair cognitive function, particularly verbal memory, visuospatial ability, and executive functions [226, 227].”
BackgroundPossible role of common spices as a preventive and therapeutic agent for Alzheimer's disease
Mirmosayyeb, O., Tanhaei, A., Sohrabi, H. R., Martins, R. N., Tanhaei, M., Najafi, M. A., Safaei, A., & Meamar, R. (2017) · International Journal of Preventive Medicine · doi:10.4103/2008-7802.199640 · Cited by 50 · cited 1×
“Other antioxidant and anti-inflammatory food sources that have also been investigated by us and others include curcumin (a component of the spice turmeric), cinnamon, ginger, and the pepper family [25, 199].”
BackgroundSelf-citationDecreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease
Müller, S., Preische, O., Sohrabi, H. R., Gräber, S., Jucker, M., Dietzsch, J., Ringman, J. M., Martins, R. N., McDade, E., Schofield, P. R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01327-w · Cited by 49 · cited 1×
“More recently, we have found that white matter hyperintensities, as measured by T2weighted MRI scans, are increased approximately 6 years before expected symptom onset in autosomal dominant AD, suggesting these changes are a core feature of AD [108]; we have also shown low body mass index appears to correlate with pre…”
BackgroundSelf-citationAre Certain Lifestyle Habits Associated with Lower Alzheimer's Disease Risk?
Arab, L., & Sabbagh, M. N. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091573 · Cited by 48
Rembach, A., the AIBL Research Group, Watt, A. D., Wilson, W. J., Villemagne, V. L., Burnham, S. C., Ellis, K. A., Maruff, P., Ames, D., Rowe, C. C., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131802 · Cited by 48
Self-citationReviewGenetics, lifestyle and the roles of amyloid β and oxidative stress in Alzheimer’s disease
Veurink, G., Fuller, S. J., Atwood, C. S., & Martins, R. N. (2003) · Annals of Human Biology · doi:10.1080/03014460310001620144 · Cited by 48
Self-citationBates, K. A., Sohrabi, H. R., Rodrigues, M. A., Beilby, J. P., Dhaliwal, S. S., Taddei, K., Criddle, A., Wraith, M. J., Howard, M., Martins, G., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1050 · Cited by 47
Self-citationAlterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease
Goozee, K., Chatterjee, P., James, I., Shen, K., Sohrabi, H. R., Asih, P. R., Dave, P., Ball, B., ManYan, C., Taddei, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00751-2 · Cited by 47
Self-citationAlzheimer's Disease and the Early Signs of Age-Related Macular Degeneration
Frost, S. M., Guymer, R. H., Aung, K. Z., Macaulay, S. L., Sohrabi, H. R., Bourgeat, P., Salvado, O., Rowe, C. C., Ames, D. J., Masters, C. L., et al. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160603003800 · Cited by 46
Self-citationNielsen, H. M., Chen, K., Lee, W., Chen, Y., Bauer, R. J., Reiman, E., Caselli, R., & Bu, G. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0231-9 · Cited by 44
The Microtubule-Associated Protein Tau and Its Relevance for Pancreatic Beta Cells
Maj, M. A., Hoermann, G., Rasul, S., Base, W., Wagner, L., & Attems, J. (2015) · Journal of Diabetes Research · doi:10.1155/2016/1964634 · Cited by 42 · cited 1×
“Tau has roles in insulin transport and secretion by the pancreatic -cells [184, 185], and can also mod-”
BackgroundYq, W., Dh, Q., & Wang, K. (2016) · PubMed · Cited by 42
Yao, J., Petanceska, S. S., Montine, T. J., Holtzman, D. M., Schmidt, S. D., Parker, C. A., Callahan, M. J., Lipinski, W. J., Bisgaier, C. L., Turner, B. A., et al. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02532.x · Cited by 41 · cited 1×
“In contrast, this age-related A increase was prevented in mice carrying the 3 allele [44].”
BackgroundSelf-citationAmyloid precursor protein modulates macrophage phenotype and diet-dependent weight gain
Puig, K. L., Brose, S. A., Zhou, X., Sens, M. A., Combs, G. F., Jensen, M. D., Golovko, M. Y., & Combs, C. K. (2017) · Scientific Reports · doi:10.1038/srep43725 · Cited by 41 · cited 1×
“The A peptide and A PP have been suggested to regulate systemic metabolism, as reviewed in [181, 182], and plasma levels of the more pathogenic A 42 are increased in T2D compared to aged matched controls [183].”
BackgroundMathur, S., Głogowska, A., McAvoy, E., Righolt, C. H., Rutherford, J., Willing, C., Banik, U., Ruthirakuhan, M. T., Mai, S., & Garcia, A. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-130866 · Cited by 40
Foster, J. K., Albrecht, M. A., Savage, G. R., Lautenschlager, N. T., Ellis, K. A., Maruff, P. T., Szoeke, C. E. I., Taddei, K., Martins, R. N., Masters, C. L., et al. (2013) · Brain · doi:10.1093/brain/awt127 · Cited by 40
Self-citationThai, C., Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Ellis, K. A., Rainey-Smith, S. R., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139082 · Cited by 40
Self-citationLim, Y. Y., Williamson, R., Laws, S. M., Villemagne, V. L., Bourgeat, P., Fowler, C., Rainey-Smith, S., Salvado, O., Martins, R. N., Rowe, C. C., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170072 · Cited by 40
Self-citationFrançois, M., Leifert, W., Hecker, J., Faunt, J., Martins, R., Thomas, P., & Fenech, M. (2014) · Cytometry Part A · doi:10.1002/cyto.a.22453 · Cited by 39 · cited 1×
“[157], yet similar significant differences were not”
Self-citationThe Role of Gonadotropins in Alzheimer's Disease: Potential Neurodegenerative Mechanisms
Barron, A. M., Verdile, G., & Martins, R. N. (2006) · Endocrine · doi:10.1385/endo:29:2:257 · Cited by 39 · cited 1×
“Evidence is mounting that age-related increases in LH may influence AD pathogenesis as it has been implicated in inflammation, changes to cholesterol homeostasis, altered metabolism of A and A PP, and insulin metabolism [231].”
BackgroundSelf-citationLuteinizing hormone acts at the hippocampus to dampen spatial memory
Burnham, V. L., Sundby, C., Laman-Maharg, A., & Thornton, J. E. (2016) · Hormones and Behavior · doi:10.1016/j.yhbeh.2016.11.007 · Cited by 39 · cited 1×
“Others have since shown that LH can influence hippocampal-related spatial memory [234], and that downregulating LH (but not estrogen therapy) can improve cognitive dysfunction and spine density loss induced by ovariectomy [235]; however, the underlying mechanisms by which these hormones influence A accumulation, metab…”
BackgroundLim, W. L. F., Lam, S. M., Shui, G., Mondal, A., Ong, D., Duan, X., Creegan, R., Martins, I. J., Sharman, M. J., Taddei, K., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.03.012 · Cited by 37
Self-citation
Research works printed but not linked: 8
- Hazar N, 2016, Iran J Neurol, 15, 164
- Watson WJ, 1984, Can Fam Physician, 30, 595
- Small GW, 1996, J Clin Psychiatry, 57, 9
- Ellis K, 2006, Acta Neuropsychiatr, 18, 285
- Fara GM, 2015, Ann Ig, 27, 693
- An Y, 2017, Alzheimers Dement
- Shi L, 2017, Sleep Med Rev
- Wang YQ, 2016, Eur Rev Med Pharmacol Sci, 20, 2389
Cited by
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Understanding mechanisms of antioxidant action in health and disease
Halliwell, B. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00645-4 · Cited by 629
“For example, vitamin E inhibits lipid peroxidation but may not prevent the increased oxidative DNA, RNA and protein damage seen in Alzheimer disease 123,156–159 .”
Zucchella, C., Sinforiani, E., Tamburin, S., Federico, A., Mantovani, E., Bernini, S., Casale, R., & Bartolo, M. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01058 · Cited by 297
Metadata
- Authors
- Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., Hone, E., Pedrini, S., Lim, W. L., Martins, I., Frost, S., Gupta, S., O’Bryant, S., Rembach, A., Ames, D., Ellis, K., Fuller, S. J., Brown, B., Gardener, S. L., Fernando, B., Bharadwaj, P., Burnham, S., Laws, S. M., Barron, A. M., Goozee, K., Wahjoepramono, E. J., Asih, P. R., Doecke, J. D., Salvado, O., Bush, A. I., Rowe, C. C., Gandy, S. E., & Masters, C. L.
- Affiliations
- Edith Cowan University (AU)
- Florey Institute of Neuroscience and Mental Health (AU)
- University of Toronto (CA)
- Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- Commonwealth Scientific and Industrial Research Organisation (AU)
- University of North Texas (US)
- The University of Melbourne (AU)
- Australian Alzheimer’s Research Foundation (AU)
- Murdoch University (AU)
- Nanyang Technological University (SG)
- The University of Western Australia (AU)
- UNSW Sydney (AU)
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Cooperative Research Centre for Mental Health (AU)
- Corresponding author
- Martins, Ralph N.
- ORCID
- Martins, Ralph N.
- Villemagne, Victor
- Sohrabi, Hamid R.
- Chatterjee, Pratishtha
- Shah, Tejal M.
- Verdile, Giuseppe
- Fraser, Paul
- Taddei, Kevin
- Gupta, Veer B.
- Hone, Eugene
- Pedrini, Steve
- Lim, Wei Ling
- Martins, Ian
- Frost, Shaun
- O’Bryant, Sid
- Ellis, Kathryn
- Brown, Belinda
- Gardener, Samantha L.
- Burnham, Samantha
- Laws, Simon M.
- Barron, Anna M.
- Goozee, Kathryn
- Wahjoepramono, Eka J.
- Asih, Prita R.
- Doecke, James D.
- Salvado, Olivier
- Bush, Ashley I.
- Rowe, Christopher C.
- Masters, Colin L.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2018-03-13
- Volume
- 62
- Issue
- 3
- Pages
- 965-992
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5870031
- OpenAlex
- W2794133158
- Cited by
- 129
- References
- 239
- Citations by year
- 2026: 1 · 2025: 14 · 2024: 15 · 2023: 18 · 2022: 18 · 2021: 24 · 2020: 23 · 2019: 13 · 2018: 3
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by-nc)
- Murdoch University Research Portal (submittedVersion)
- Australasian Journal of Paramedicine (submittedVersion, cc-by-nc)
- Deakin Research Online (Deakin University) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Figshare (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta
- MeSH terms
- Alzheimer Disease, Animals, Australia, Humans, Biomarkers, Oxidative Stress, Amyloidogenic Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.